EIF4E and neoplasm: Finally, despite robust activities in blocking eIF4E phosphorylation at S209, none of the 2 MNK1/2 inhibitors exhibited notable tumor-inhibiting activities in any of the tumor cell lines we tested, including the MAPK4-low and MAPK4-KO cancer cell lines (S3C and S3D Fig).